Credit: Reuters/Robert Galbraith/Files
The Amgen corporate logo is seen at the company's office in South San Francisco, California in this file photo taken October 21, 2013.
Amgen's share rose 4.3 percent to $130.96 in premarket trading on Monday after the company released the interim data from a late-stage study.
The trial was testing the drug, Kyprolis, in combination with two other treatments, against those treatments alone in previously-treated patients with relapsed multiple myeloma.
(Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)
